



**Universiteit  
Leiden**  
The Netherlands

## **Pharmacist-driven interventions in patients with chronic kidney disease and end-stage renal failure**

Oever, F.J. van den

### **Citation**


Oever, F. J. van den. (2026, March 12). *Pharmacist-driven interventions in patients with chronic kidney disease and end-stage renal failure*. Retrieved from <https://hdl.handle.net/1887/4296592>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4296592>

**Note:** To cite this publication please use the final published version (if applicable).



# CHAPTER 2

## Algorithm-managed dosing and pharmacist-managed dosing of erythropoietin-stimulating agents in renal anaemia: a systematic review

F.J. van den Oever, M.J.E. Dekker, E.C. Vasbinder,  
T. van Gelder, P.M.L.A. van den Bemt

## Abstract

### Objectives

The goal of this systematic review was to identify and summarise algorithm- and pharmacist-managed dosing of erythropoietin-stimulating agents (ESA) in patients with renal anaemia and to determine the effects on available outcome parameters.

### Methods

We followed the PRISMA guidelines for systematic reviews. Studies investigating algorithm-managed and pharmacist-managed dosing of ESA in adult patients with renal anaemia were evaluated for inclusion. No restrictions were set on outcome parameters. Observational and interventional studies available as full-text articles with a control group and follow-up  $\geq 6$  months were eligible for inclusion. Relevant databases were searched from their inception through August 2024. Two independent reviewers evaluated all studies. The risk of bias was assessed by the ROBINS-I and RoB1 tools. The protocol of this study was registered in PROSPERO (CRD42021243678). Franciscus Gasthuis and Vlietland Hospital funded this study.

### Results

After screening 140 articles, 17 articles and 4313 patients could be included. Available evidence was of low to moderate quality with a high risk of bias. Data were summarised and tabulated. Meta-analysis was not possible due to the substantial heterogeneity in participants, study design, interventions, comparisons, and outcome parameters. However, standardised metrics could be identified and calculated for haemoglobin and ESA dose. The percentage in target range for haemoglobin varied between 3.5% lower (95%CI -18.67% to + 11.67%) to 32.0% higher (95%CI 14.07 to 49.93%) in the pharmacist-managed group versus the control group (n=1401). The range in reduction in ESA dose was 5.45% (95%CI -7.97% to + 18.87%) to 49.97% (95%CI 20.32% to 79.61%) in the pharmacist-managed group versus the control group (n=2115).

### Conclusion

Low-quality data with high risk of bias suggest that pharmacist-managed renal anaemia may improve the percentage of haemoglobin within target range and reduce the ESA dose. However, meta-analysis was impossible due to substantial heterogeneity. Therefore, no definite conclusions could be drawn on the effectiveness of pharmacist-managed dosing of ESA in renal anaemia.

## Introduction

With the progression of chronic kidney disease (CKD), the prevalence of renal anaemia increases. Notwithstanding the emergence of new treatment strategies, erythropoietin-stimulating agents (ESA) still are the cornerstone of renal anaemia treatment. Up to 90 per cent of haemodialysis patients in Europe are on ESA <sup>1</sup>. For ESA to be optimally effective, iron status needs to be optimised. Therefore, iron supplementation is indicated when patients are on ESA unless otherwise contraindicated <sup>2</sup>.

Haemoglobin target levels for the treatment of renal anaemia have changed over the years. Haemoglobin levels should not be fully corrected, as target levels towards the normal range are associated with increased mortality <sup>3,4</sup>, whereas levels below 6.2 mmol/L are associated with a lower quality of life and a higher transfusion rate <sup>5</sup>. Therefore, current guidelines recommend target levels between 6.2 and 7.1 mmol/l for haemoglobin in haemodialysis patients <sup>2,6</sup>.

In clinical practice, it is challenging to meet these target levels. Without the use of decision aids, only about 30% of the haemodialysis patients in Europe have within-target haemoglobin values <sup>1</sup>. Several factors impede the attainment of target levels, such as ESA hyporesponsiveness and infections, but also the suboptimal prescribing of ESA and iron plays a role <sup>1,7</sup>. Suboptimal prescribing may occur because of the clinician's focus on low haemoglobin levels and the prevention of transfusions, whereas high haemoglobin levels are frequently overlooked. This often leads to the erroneous continuation of a too-high dose of ESA, which occurs in more than a quarter of haemodialysis patients in Europe <sup>1</sup>.

Various interventions to improve the treatment of renal anaemia have been investigated, such as the introduction of treatment algorithms <sup>8,9</sup>, and pharmacist-managed anaemia programs <sup>10-13</sup>. However, the effectiveness of these interventions remains inconclusive, as outcomes are highly variable, and a structured, thorough analysis is lacking. To address this important knowledge gap, we systematically reviewed the available literature and summarised the evidence. We aimed to identify the various methods of algorithm-managed and pharmacist-managed dosing of erythropoietin-stimulating agents in adults with renal anaemia. In addition, we aimed to summarise the current literature

on the effectiveness of algorithm-managed and pharmacist-managed dosing of erythropoietin-stimulating agents in renal anaemia.

## **Methods**

This systematic review on algorithm-managed and pharmacist-managed dosing of erythropoietin-stimulating agents (ESA) in adults with renal anaemia followed the PRISMA and PRISMA-P guidelines. The protocol of this study was registered in PROSPERO (International Prospective Register of Systematic Reviews, ID CRD42021243678).

### **Data sources and searches**

The search strategy was designed and implemented in collaboration with a medical librarian. The following databases were searched from their inception through August 2024: PubMed, Embase, Web of Science, and the Cochrane Library. Search terms included a combination of keywords and the following MeSH terms: “chronic kidney disease”, “renal failure”, “haemodialysis”, “peritoneal dialysis”, “anaemia”, “renal anaemia”, “renal replacement therapy”, “end-stage renal disease”, “pharmacist”, “erythropoietin stimulating agents”, “epoetin” and “algorithm”. The search strategy was tailored for each database. No language restrictions were placed on the search. Reference lists of relevant articles and previous systematic reviews<sup>14-16</sup> were manually searched for any additional relevant studies. The full search strategy is available as supplementary material.

### **Study selection and eligibility criteria**

We included studies that explored the effect of algorithm-managed and pharmacist-managed dosing of ESA in adult patients with renal anaemia as compared to usual care. No restrictions were set on outcome parameters. All observational and interventional studies that included a control group without the use of algorithm-managed or pharmacist-managed dosing, and had a follow-up of at least six months, were eligible for inclusion.

Only full-length articles were considered for inclusion in this review. Titles and abstracts of the articles were screened to include relevant studies. When insufficient information was available from the title or abstract of a paper, a full

copy of the article was obtained and screened to determine eligibility. Each article was independently evaluated for inclusion by two reviewers (FJvdO and TvG) and disagreements between the reviewers were resolved by discussion with the third reviewer (PvdB).

### **Data extraction**

Standardised data extraction forms were developed. Data extraction was carried out independently by two authors (FJvdO and MJED), and disagreements were resolved through discussion and consensus. Information extracted from the studies included: title, author, year of publication, country of origin, study design (retrospective, cross-sectional, etc.), setting, population details, number of patients, duration, comparison, and outcomes of interest. Furthermore, detailed information about the interventions and algorithms was extracted. This included an intervention description and determination of the type of intervention (algorithm-based or not, pharmacist-managed or not). Also, the quality of the intervention description was scored and reproducibility was assessed. Reproducibility was scored as yes or no, this score was assessed by determining if the intervention description was detailed enough to reproduce the intervention in clinical practice. Specific aspects of the used algorithms were determined, such as input and output parameters, whether it was computerized, and if its description was complete.

### **Quality assessment and risk of bias**

Two reviewers (FJvdO and MJED) independently assessed the quality and risk of bias of the studies eligible for inclusion, except if one of them was involved as an author of an included study; in that case, a third reviewer (PvdB) assessed the quality and risk of bias instead of the author. For RCTs, the Risk of Bias (RoB2) tool for assessing the risk of bias in randomised trials was used<sup>17</sup>. For non-randomised interventional studies, The Risk Of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool was used<sup>18</sup>. To assess the quality of included studies, the Quality Assessment Tool for Quantitative Studies (Effective Public Health Practice Project 2007) was used (Ottawa Hospital Research Institute (ohri.ca), 2022-08-11). To reduce the risk of bias due to missing results, we checked the trial register [clinicaltrials.gov](http://clinicaltrials.gov).

### **Data synthesis and analysis**


We planned to analyse data using a systematic quantitative synthesis of included studies, according to the Cochrane Handbook on Systematic Reviews<sup>19</sup>. Quantitative

synthesis was to be performed for data regarding the most frequently investigated haemoglobin outcomes and ESA dose or cost parameters. For quantitative synthesis, for each outcome of interest, at least three studies needed to be available. We planned to transform the intervention effects into the standardised metric by calculation. The predefined standardised metrics were the mean differences in the haemoglobin outcome and erythropoietin dose or expenditure. The standard metric would be selected based on the most frequently reported outcome parameter in included studies. In case a formal meta-analysis would not be possible, we would perform a SWiM (Synthesis Without Meta-analysis)<sup>20</sup>, with the intention to summarise the effect estimates and provide GRADE recommendations. Study data were summarised and tabulated. Studies were prioritised based on study design, risk of bias assessment, and quality assessment. We planned to create forest plots to display the effects of the interventions on the predefined standardised metrics. Heterogeneity was informally explored: studies were grouped according to population (haemodialysis, peritoneal dialysis, and chronic kidney disease) and risk of bias.

## Results

### Search results and study selection

A flow chart of the literature search and identification of relevant articles for review is depicted in Figure 1. Overall, 140 eligible articles were identified. Seventeen articles complied with the inclusion criteria and are summarised and evaluated in this systematic review, with a total of 4313 patients in 16 studies. In one study, no patient numbers could be identified<sup>21</sup>, in two articles, the same patient population was studied<sup>11,12</sup>.



**Figure 1.** Flow chart of literature search and identification of relevant articles

### Study characteristics

Table 1 shows the characteristics of included studies (n=17). Six studies were performed in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD), and eleven studies were performed in patients on haemodialysis. In one of these studies, patients on peritoneal dialysis were also included. Study follow-up was relatively short, varying between six and thirteen months.

**Table 1.** Study characteristics and outcome data

| Study          | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison            | Primary outcome             | Secondary outcomes | Results   |
|----------------|--------|---|--------------|--|-----------------------------|--------------------|---|
| Armstrong 2000 | I-RCT  | HD<br>Intervention n= 219<br>Control n=212<br>12 m FU               | P&A          | Anaemia management by the nephrologist | *<br>Ht 33 ±3% current week |                    | Ht 33 ±3% current week<br>I: 51.6% C:50.9%<br><br>2 of last 4 Ht readings in last month within 33±3%<br>I:79.0% C:81.3%<br><br>80% of Ht obtained over the last 6 months >30% and < 36%<br>I: 21.0% C: 15.4%<br><br>No P-values or CIs reported |

**Table 1.** Study characteristics and outcome data (continued)

| Study             | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison            | Primary outcome  | Secondary outcomes  | Results   |
|-------------------|--------|---|--------------|--|--|---|---|
| Vanden Oever 2020 | i-RCT  | HD<br>Intervention n=100<br>Control n=100<br>13 m FU                | P&A          | Anaemia management by the nephrologist | Median percentage of monthly Hb values in the follow-up period that were in the target range (PTR, Hb target 11-12 g/dL) | Percentage of Hb levels in supra-therapeutic range (PSTR, Hb >13 g/dL)<br><br>PTR for iron (TSAT ≥ 20% and ferritin 200-500 mg/L)<br><br>Percentage of Hb levels below target range (PBTR, Hb <6.8 mmol/L)  | PTR for Hb<br>I: 38.5% C: 23.1% p=0.001<br><br>PSTR for Hb<br>I: 0.0% C: 7.7% p=0.034<br><br>PTR for iron<br>I: 21.1% C: 8.3% p=0.003<br><br>PBTR for Hb<br>I: 30.8% C: 30.8% p=0.864 |
|                   |        |   |              |  | Post-hoc analyses:<br>Darbepoetin alfa (DA) dose (weekly)<br><br>Iron sucrose dose (weekly)                              | DA dose (mcg)<br>I: 34.0 C: 46.9 p=0.020<br><br>Iron sucrose dose (mg):<br>I: 75.0 C: 0.0 p<0.001   |   |
|                   |        |   |              |  | All-cause mortality<br><br>Number of patients with at least one transfusion during follow-up<br><br>Robustness           | All-cause mortality (n)<br>I: 16 C: 26 p=0.096<br><br>Patients with at least 1 transfusion (n, %):<br>I: 19 (20.2%) C: 31 (34.1%) p=0.046<br><br>Robustness (range PTR for Hb between different healthcare givers)<br>I: 30.3% to 42.9% C: 15.4% to 43.0% |   |

**Table 1.** Study characteristics and outcome data (continued)

| Study                | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison   | Primary outcome   | Secondary outcomes  | Results   |
|----------------------|--------|---|--------------|---|---|---|---|
| Dashti-Kavidaki 2012 | I-PP   | HD<br>n=86<br>6 m FU  | P            | Patients were their own controls<br>Anaemia management by the nephrologist                            | #<br>Aim of the study: effect of clinical pharmacy services on management of secondary complications such as anaemia          | Average number of iron tests per patient during the 6-month study period        | Hb in optimal range (11-12 g/dL):<br>I: 15.1% C: 18.6% p=0.664<br><br>Ferritin in optimal range (100-800 ng/mL)<br>I: 76.2% C: 48.8% p not reported<br><br>TSAT in optimal range (20-50%)<br>I: 34.7% C: 45.3% p not reported |
| Aspinall 2012        | O-RC   | CKD-NDD<br>I: n= 314<br>UCE: n= 91<br>UC: n=167<br>6 m FU           | P            | Usual care site (UC) and usual care at ESA clinic (UCE)<br><br>Anaemia management by the nephrologist | Proportion of Hb values in target range (Hb 10-12 g/dL)<br>ESA dose<br>Intra- and interpatient variance in haemoglobin values | Average number of Hb and iron tests per patient during the 6-month study period | Proportion of Hb values in target range<br>I: 71.1% UC: 56.9% p<0.001 UCE: 51.7%<br><br>ESA dose monthly (geometric means)<br>Darbeoetin alfa:<br>I: 115mcg UC: 156mcg p=0.049 UCE: 181 mcg                                   |

**Table 1.** Study characteristics and outcome data (continued)

| Study                     | Design | Population (including number of patients and duration of follow-up) | Inter-vention | Control group or comparison | Primary outcome | Secondary outcomes | Results   |
|---------------------------|--------|---|---------------|-----------------------------|-----------------|--------------------|---|
| Aspinall 2012 (continued) |        |   |               |                             |                 |                    | <p>Epoetin alfa:<br/>                     I: 29,677 IU UC: 32,856 IU p=0.6<br/>                     UCE:39,258 IU</p> <p>Inpatient variance Hb:<br/>                     I:0.66 UC:0.71 UCE:1.03 (no p-values)</p> <p>Interpatient variance Hb:<br/>                     I:0.51 UC: 1.89 UCE: 14.6 (no p-values)</p> <p>Number of Hb tests<br/>                     I: 5.8 ±2.6 UC: 3.6±3.0 UCE: 3.8 ±2.8<br/>                     p=0.007</p> <p>Number of iron tests<br/>                     I: 2.2±1.6 UC: 1.0±1.1 UCE:1.1±1.2<br/>                     p=0.001</p> <p>≥ 1 TSAT measurement:<br/>                     I: 64.7% UC: 32.3% p=0.08 UCE:37.4%</p> |

**Table 1.** Study characteristics and outcome data (continued)

| Study         | Design | Population (including number of patients and duration of follow-up)              | Intervention | Control group or comparison                  | Primary outcome  | Secondary outcomes | Results   |
|---------------|--------|--|--------------|--|--|--------------------|---|
| Aspinall 2013 | O-RC   | CKD-NDD<br>I: n=314<br>C: n=167<br>Same population as in Aspinall 2012<br>6 m FU | P            | Anaemia management by the nephrologist       | #<br>Objective:<br>To compare the cost-effectiveness of pharmacist-managed erythropoiesis-stimulating agent (ESA) clinics with that of usual care in patients with non-dialysis-dependent (NDD) CKD. |                    | PM: Cost per patient was \$2,761 less, and ESA clinic strategy was more effective (+0.003 QALYs)<br><br>Sensitivity analyses:<br>Results were robust to variation   |
| Bucaloiu 2007 | O-RC   | CKD-NDD<br>I: n=62<br>C: n=74<br>6-12 m FU                                       | P            | Anaemia management by primary care physician | *<br>Percentage of time at target Hb<br>Percentage of time at target Hb<br>Percentage of time at target TSAT<br>Time to target Hb  |                    | Percentage of time at target Hb<br>I: 69.8% C: 43.9% p<0.001<br><br>Percentage of time at target TSAT<br>I: 64.8% C: 40.4% p=0.043<br><br>Time to target Hb<br>I: 47.5 days C: 62.5 days p=0.11<br><br>Weekly ESA dose<br>I: 6698 IU C: 12000 IU p<0.0001 |

**Table 1.** Study characteristics and outcome data (continued)

| Study         | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison            | Primary outcome  | Secondary outcomes  | Results  |
|---------------|--------|---|--------------|--|--|---|--|
| Debenito 2014 | O-RC   | CKD-NDD<br>I: n=31<br>C: n=70<br><br>6 m FU                         | P            | Anaemia management by the nephrologist | Rates of adherence to 6 monitoring recommendations for Hb and iron status<br><br>(a) baseline Hb (b) first follow-up Hb < 4 weeks after start ESA (c) further follow-up Hb ≤ 4 weeks apart; (d) baseline ferritin and TSAT; (e) follow-up ferritin and TSAT levels measured at least once (f) iron therapy initiated within 14 days of lab test if ferritin < 100 ng/mL or TSAT <20% | Proportions of:<br><br>-patients achieving target Hb levels<br><br>-number of days required to achieve target<br><br>-patients experiencing at least 1 Hb higher than 12 g/dL or below 10 g/dL<br><br>-patients receiving at least 1 red blood cell transfusion<br><br>-patients with at least 1 hospital visit defined as an anaemia- or ESA-related hospitalisation or emergency department visit<br><br>Average weekly dose of ESA therapy and associated cost | Composite Hb monitoring endpoint (a-c, all three items)<br>I: 32.3% C: 14.3% p=0.049<br><br>Composite iron monitoring endpoint (d and e)<br>I: 62.3% C: 30.0% p=0.005<br><br>Patients achieving target Hb (Hb 10-12 g/dL)<br>I: 96.8% C: 95.7% p=0.654<br><br>Mean days to achieve Hb target:<br>I: 28 C: 41 p=0.135<br><br>Any follow-up Hb > 12 g/dL:<br>I: 48.4% C: 54.3% p=0.715<br><br>Any follow-up Hb < 10 g/dL:<br>I: 64.5% C: 60.0% p=0.673<br><br>Patients with at least one transfusion<br>I: 9.7% C: 15.7% p=0.439 |

**Table 1.** Study characteristics and outcome data (continued)

| Study                     | Design | Population (including number of patients and duration of follow-up) | Inter-vention | Control group or comparison | Primary outcome   | Secondary outcomes | Results  |
|---------------------------|--------|---|---------------|-----------------------------|---|--------------------|--|
| Debenito 2014 (continued) |        |   |               |                             | Composite outcomes consisting of Hb monitoring (items a-c), and iron monitoring (items d-e) |                    | <p>Patients with at least 1 hospital visit<br/>I: 3.2% C:20.0% p=0.067</p> <p>Iron therapy started within 14 days if necessary;<br/>I: 75.0% C: 46.0% p=0.016</p> <p>Weekly ESA dose<br/>I: 5509IE C: 6877 IE p&lt;0.001</p> <p>Annual ESA cost<br/>I: 5109\$ C: 6397\$ p&lt;0.001</p> |

**Table 1.** Study characteristics and outcome data (continued)

| Study           | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison                                 | Primary outcome  | Secondary outcomes  | Results  |
|-----------------|--------|---|--------------|---|--|---|--|
| Dubovetsky 2022 | O-RC   | HD<br>I: n=61<br>C: n=68<br>6 m FU                                  | P&A          | Anaemia management by the nephrologist, historical controls | Percentage of time in therapeutic range (TTR) for Hb 9.5-10.9 g/dL | Differences in mean weekly ESA dose<br><br>Number of red blood cell transfusions<br><br>Percentage of Hb values in categories $\leq 8.5$ g/dL, 8.6-9.4 g/dL, 9.5-10.9 g/dL, 11-11.9 g/dL, and $\geq 12$ g/d at end of study;<br><br>Median ferritin values<br><br>Median TSAT<br><br>Total iron doses per patient<br><br>ESA-associated costs | TTR for Hb:<br>I: 30.7% C: 29.3% p=0.177<br><br>Weekly ESA dose:<br>I: 10064 U C: 15227 U p=0.035<br><br>Red blood cell transfusions (n):<br>I: 0.3 C: 0.6 p=0.255<br><br>Percentage in different Hb categories: no differences<br><br>Ferritin:<br>I: 629 ng/mL C: 386 ng/mL p=0.016<br><br>TSAT:<br>I: 24.5% C: 22% p=0.055<br><br>Total iron doses per patient:<br>I: 1200 mg C: 900 mg p=0.060<br><br>ESA-associated costs:<br>I: 154\$ C: 233\$ p=0.035 |

**Table 1.** Study characteristics and outcome data (continued)

| Study         | Design | Population (including number of patients and duration of follow-up)    | Intervention | Control group or comparison                                 | Primary outcome   | Secondary outcomes | Results  |
|---------------|--------|--|--------------|---|---|--------------------|--|
| EiNekidy 2020 | O-RC   | HD<br>N=163<br>12 m FU before (C) and 12 months after intervention (I) | P&A          | Anaemia management by the nephrologist, historical controls | Aim of the study was to assess the impact of the nephrology pharmacist on the proportion of patients who achieve Hb goals with optimised ESA and iron consumption, iron indices (TSAT and ferritin), blood transfusions, and iron dosing strategy |                    | Mean Hb: I:108.3±9.4 g/L C:109.5±9.5 g/L p=0.1586<br>Transfusion rate: I:1.8% C:1.3% p=0.196<br>Weekly ESA dose: I:11364.1±52 U C:12315.6±8 U p=0.0556<br>Monthly iron dose (iv): I:215.4±90 C:215.4±100 p=0.9968<br>TSAT: I:0.307±0.05 C:0.305±0.11 p=0.8386<br>Ferritin (ng/mL) I:317.1±12 C:273.5±22 p=0.0019 |

**Table 1.** Study characteristics and outcome data (continued)

| Study    | Design | Population (including number of patients and duration of follow-up)                                | Intervention | Control group or comparison                                 | Primary outcome   | Secondary outcomes   | Results   |
|----------|--------|--|--------------|---|---|--|---|
| Joy 2007 | O-RC   | CKD-NDD<br>I:n=99<br>C:n=29<br>Total study period =28 months (follow-up per patient not mentioned) | P&A          | Anaemia management by the nephrologist, historical controls | Proportion of patients with $\geq$ 30 days of ESA treatment who achieved target Hb level $\geq$ 11.0 g/dl | Hb level, darbepoetin alfa dose, and darbepoetin alfa administration frequency<br><br>Secondary Hb outcomes: length of time to attain target Hb for naïve patients (Hb $\geq$ 11.0 g/dl)<br><br>Hb at target attainment<br><br>Last available Hb level | Attainment of Hb target level I: 78% (mean Hb $\pm$ SD 11.7 $\pm$ 7 g/dl) C: 41%<br><br>Length of time to attain target Hb: I: 7.9 $\pm$ 7.5 weeks C: 6.1 $\pm$ 2.7 weeks<br><br>Mean Hb level at target achievement I: 11.7 $\pm$ 0.7 g/dL C: 11.4 $\pm$ 0.3 g/dL<br><br>Last available Hb level for all patients (n=134): 10.9 $\pm$ 1.5 g/dL<br><br>Weekly dose DA: 10-100 mcg per week (no further data reported)<br><br>Dosing interval DA:<br>Every 2 weeks: 82%<br>Every 3 weeks: 14%<br>Every 4 weeks: 4%<br><br>No P-values reported |

**Table 1.** Study characteristics and outcome data (continued)

| Study       | Design | Population (including number of patients and duration of follow-up) | Inter-vention | Control group or comparison                                 | Primary outcome  | Secondary outcomes | Results  |
|-------------|--------|---|---------------|---|--|--------------------|--|
| Kimura 2004 | O-RC   | HD<br>N=41<br>FU=9 months   | P&A           | Anaemia management by the nephrologist, historical controls | #<br>Therapeutic and pharmacoeconomic outcomes were evaluated. |                    | Haematocrit >30% (therapeutic target)<br>I: 78.0% C: 17.1%<br><br>Average Ht<br>I: >30% C: 28.5%<br><br>Monthly consumption of epoetin beta<br>I: 624000 IU C: 91.5000 IU<br><br>Change in monthly cost of epoetin beta<br>I: 1.37 mln yen C: 1.86 mln yen<br><br>No P-values reported |

**Table 1.** Study characteristics and outcome data (continued)

| Study     | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison | Primary outcome  | Secondary outcomes   | Results   |
|-----------|--------|---|--------------|-----------------------------|--|--|---|
| Linn 2023 | O-RC   | HD (hospitalised)<br>N=264 (pre)<br>N=272 (post)<br>FU=6 months     | P            | Not described               | Average acquisition cost of epoetin alfa-epbx (epoetin zeta) per patient | Average monthly purchasing cost during the study period<br>Overall purchasing cost of epoetin alfa-epbx<br>Average dose of epoetin alfa-epbx<br>Average number of administered doses per patient<br>Percentage of patients experiencing stroke or thrombosis<br>Percentage of patients receiving blood transfusion(s) during admission | Average acquisition cost per patient:<br>I: \$1,041.35 C: \$1,681.77 p<0.0001<br><br>Average monthly purchasing cost<br>I: \$21,312.21 C: \$24,828.48 p=0.5594<br><br>Overall purchasing cost<br>I: \$127,873.25 C: \$148,970.89 vs no p-value<br><br>Average dose<br>I: 10,112 units C: 13,694 p=0.0004<br><br>Average number of administered doses per patient<br>I: 1.79 C: 2.09 doses p = 0.0668<br><br>No differences between the incidence of stroke, thrombosis, and RBC transfusion |

**Table 1.** Study characteristics and outcome data (continued)

| Study        | Design | Population (including number of patients and duration of follow-up)                              | Intervention | Control group or comparison                                 | Primary outcome  | Secondary outcomes | Results  |
|--------------|--------|--|--------------|---|--|--------------------|--|
| Ohnishi 2011 | O-RC   | HD<br>N=84<br>FU=12 months   | P&A          | Anaemia management by the nephrologist, historical controls | #<br>Examination of the influence of having pharmacists actively manage Hb levels on therapeutic outcome   |                    | Number of patients with optimal levels of Hb at start of follow-up:<br>I: 45 C: 40 p=0.07<br><br>Number of patients with optimal levels of Hb at end point:<br>I: 61 C:46 p=0.03   |
| Quercia 2001 | O-RC   | HD<br>N=?<br>1994: historical control<br>1995 and 1998 after the intervention<br>Cross-sectional | P            | Anaemia management by the nephrologist, historical controls | #<br>Goals were to initiate a continuing pharmacy service that results in safe and effective management of anaemia in haemodialysis patients and to determine if a pharmacist-managed anaemia program leads to cost avoidance with regard to epoetin alpha |                    | Ht <31%:<br>1994: 32%<br>1995: 21%<br>1998: 14%<br><br>Cost avoidance by pharmacy management:<br>1994: n=109 ESA dose per patient: 5.636 U total costs: \$856.197<br>1995: n=114 patients ESA dose per patient: 4.425 U, total costs: \$704.313<br>Cost avoidance: \$191.159<br><br>1998: n=119 ESA dose per patient: 5764 U<br>total cost \$ 1.161.660<br>Cost avoidance: 203.985<br><br>No P-values reported |

**Table 1.** Study characteristics and outcome data (continued)

| Study       | Design | Population (including number of patients and duration of follow-up)  | Intervention | Control group or comparison                                 | Primary outcome  | Secondary outcomes   | Results  |
|-------------|--------|--|--------------|---|--|--|--|
| Rogers 2011 | O-RC   | CKD-NDD<br>C: n=390<br>I: n=494<br>FU= 6 months before and 6 months after intervention<br>Non-inferiority design | A            | Anaemia management by the nephrologist, historical controls | Percentage of measured Hb and transferrin saturation levels within target range (11-12 g/dL and 22%-50%, respectively) | Weekly dose and number of dose changes for epoetin alfa, darbepoetin, and iron | Percentage in target range Hb:<br>I: 34.2% C: 33.3%<br>CI for the difference: -2.5 to 4.4<br><br>Percentage in target range TSAT:<br>I: 56.9% C: 58.8%<br>CI for the difference: -3.4 to 7.7<br><br>Mean doses:<br>epoetin alfa<br>I: 3529 U C: 3270 U p= 0.85<br>Darbepoetin alfa<br>I: 20.4 µg C: 18.8 µg p= 0.59<br>Iron<br>I: 1042 mg C: 1044 mg p= 0.98 |

**Table 1.** Study characteristics and outcome data (continued)

| Study                   | Design            | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison  | Primary outcome   | Secondary outcomes | Results  |
|-------------------------|-------------------|---|--------------|--|---|--------------------|--|
| Gonzalez Fernandez 2013 | O-RCS<br>HD<br>PD | CKD-NDD<br>HD<br>PD<br>I:n= 215<br>C:n=329                          | P&A          | Anaemia management by the nephrologist, historical controls            | Aim of the study was to describe and evaluate the effectiveness of a program to adjust the prescription and dispensing of ESA |                    | Hb in target range<br>PD: I:73% C: 64% p=0.2<br>CKD-NDD: I: 75% C: 60% p=0.2<br>HD: I: 89% C: 57% p<0.001  |
|                         |                   | Cross-sectional   |              |  |   |                    | Darbeopetin alfa dose (mcg)<br>PD: I: 147.4±167.47 C: 155.9±136.5<br>p=0.434<br>CKD-NDD: I: 73.105±69.64 C: 146.1<br>±137.1 p=0.001<br>HD: I: 115.23±83.02 C: 162.3±127<br>p=0.012 |
| Walton 2005             | &                 | HD<br>N=278   | P&A          | Anaemia management by the nephrologist<br>Comparison with USA averages |   |                    | Monthly ESA cost:<br>PD: I: €121 C: €177 p not reported<br>CKD-NDD: I: €84 C: €110 p not reported<br>HD: I: €110 C: €209 p not reported  |
|                         |                   |   |              |  |   |                    | Hb:<br>I: 11.8g/dL C: 9.5g/dL<br>US average: 11.9g/dL<br>Hb >11g/dL:<br>I: 80% C: 25%<br>US average: increase from 26.1 to 75%   |

**Table 1.** Study characteristics and outcome data (continued)

| Study                   | Design | Population (including number of patients and duration of follow-up) | Intervention | Control group or comparison | Primary outcome   | Secondary outcomes | Results  |
|-------------------------|--------|---|--------------|-----------------------------|---|--------------------|--|
| Walton 2005 (continued) |        |   |              |                             | The primary objective of this study was to describe the pharmacist-managed anaemia program in an outpatient haemodialysis clinic and evaluate the program by comparing the results to the US averages |                    | Ferritin: I: 431 ± 232.1 ng/ml C: 280.9 ± 326.4 ng/ml<br>TSAT: I: 33±8% C: 21±7.9%<br>Weekly ESA dose: I:121.6 U/kg/week US average: 229 U/kg/week<br>Annual cost avoidance: \$3000 per patient<br>P-values not reported |

Abbreviations: A: algorithm-based; C: control; CI: confidence interval; CKD-NDD: chronic kidney disease, non-dialysis dependent; DA: darbepoetin alfa; ESA: erythropoiesis stimulating agent, e.g. darbepoetin alfa, epoetin alfa, etc; FU: follow-up; Hb: haemoglobin; HD: hemodialysis; Ht: haematocrit; I: intervention; I-PP: interventional, pre post design, patient is own control; I-RCT: interventional, RCT; O-RC: observational, retrospective cohort; O-RCS: observational, retrospective cross-sectional; N=number; P: pharmacist-based; PD : peritoneal dialysis; P&A: pharmacist-based and algorithm-based; QALY: quality adjusted life year; RCT: Randomized, controlled trial; TSAT: transferrin saturation; TTR: time in therapeutic range

\* Outcome parameters not defined as primary or secondary

# Outcome parameters not defined

& Study design could not be determined

## Intervention characteristics

Table 2 shows the intervention description, including the algorithm characteristics of the sixteen included studies.

**Table 2.** Intervention description and algorithm characteristics

| Study          | Intervention description  | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input   |
|----------------|---|--|---|
| <b>I-RCTs</b>  |   |  |   |
| Armstrong 2000 | <p>At least 1 pharmacist at each study site completed an intensive 4-day training session on the management of patients undergoing long-term haemodialysis, use of the software system and review of the specific DUE criteria. Education about the DUE (drug use evaluation) process and each criterion was also provided during each training session. In addition, a site validation visit was conducted to explain the data collection and processing of the DUE. Working in collaboration with the nephrologist responsible for each study patient, the trained pharmacist was responsible for monitoring, evaluating and recommending initial and subsequent epoetin alfa dosage regimens for patients in the treatment group.</p> <p>The pharmacist recommended dosages for epoetin alfa and iron based on a computer software program (EPO-CALC®). This program was based on computer-modelled algorithms for epoetin alfa and iron dose optimisation</p> | Yes, computer-based  | The software used its internal haematocrit and iron databases, along with blood pressure and laboratory data from databases manually entered by the pharmacist to calculate the DUE results. The software automatically determined whether 6- and 12-month criteria were met by examining process indicators (e.g. monitoring of iron stores) and clinical outcome measures (e.g. haematocrit values within the desired range). |

| Algorithm output                      | Algorithm available? | Level of detail of intervention description?<br>Description complete?        | Quality of the intervention description | Is intervention reproducible? |
|---------------------------------------|----------------------|--|---|-------------------------------|
| Process indicators<br>Adverse effects | No                   | Reasonably detailed intervention description<br><br>Description not complete | Moderate                                | No                            |

**Table 2.** Intervention description and algorithm characteristics (continued)

| Study  | Intervention description  | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input   |
|--|---|--|---|
| Van den Oever 2020                               | Two pharmacist investigators developed treatment algorithms for darbepoetin alfa (DA) and iron sucrose, based on SPC and the renal anaemia guideline. Principles of the treatment algorithms were discussed with the nephrologists and agreed upon. Four pharmacists provided dose advice, two of them being the investigators and two additional pharmacists, after instruction. Monthly laboratory analyses were performed (Hb, TSAT, ferritin). Pharmacists monthly recommended dosages for epoetin alfa and iron based on treatment algorithms, depending on laboratory analyses. Dose recommendations were communicated by email and when agreement was reached, the nephrologist prescribed the agreed doses. | Yes, manual  | Algorithm for DA based on actual Hb and change in Hb<br><br>Algorithm for iron sucrose based on TSAT and ferritin |
| <b>Intervention pre-post study</b>               |   |  |   |
| Dashti-Kavidaki 2012                             | Patients on maintenance HD were managed by clinical pharmacists participating in medical team rounds; all patients were evaluated for anaemia parameters (serum Hb, ferritin concentrations and TSAT). Ferritin concentrations and TSAT were evaluated every three months in stable subjects, and monthly in patients whose drugs were dose-adjusted. Parenteral erythropoietin and intravenous iron sucrose were used to manage anaemia.   | Unknown  | NA  |
| <b>Observational, retrospective cohort study</b> |   |  |   |
| Aspinall 2012                                    | Pharmacist-managed ESA clinics: Pharmacists' scope of practice allowed them to dose and monitor ESA therapy. Patients at most sites were referred to the pharmacist-managed ESA clinic by a medical provider. Study clinics had been operational since at least August 1, 2008, and evidence-based protocols were in place for the management of patients receiving ESAs. Pharmacists were responsible for dosing and management of ESA therapy. Iron testing (ferritin, serum iron or TSAT) was performed. It is unclear whether pharmacists also prescribed iron therapy. No further description was available.   | Unknown  | NA  |

| Algorithm output   | Algorithm available? | Level of detail of intervention description?<br>Description complete?                   | Quality of the intervention description | Is intervention reproducible? |
|--|----------------------|---|---|-------------------------------|
| <p>Dose advice DA: withhold DA for 4 weeks, after that, restart with 25% lower dose; dose decrease with 25%; same dose; dose increase with 25%; and dose increase with 50%</p> <p>Dose advice iron sucrose:<br/>no iron sucrose, iron sucrose 100 mg every two weeks, iron sucrose 100 mg once a week, and iron sucrose 100 mg thrice a week</p> | Yes                  | <p>Quite detailed intervention description</p> <p>Intervention description complete</p> | Moderate to high                        | Yes                           |
| NA   | NA                   | <p>Intervention minimally described</p> <p>Description not complete</p>                 | Low                                     | No                            |
| NA   | NA                   | <p>Intervention minimally described</p> <p>Description not complete</p>                 | Low                                     | No                            |

**Table 2.** Intervention description and algorithm characteristics (continued)

| Study         | Intervention description  | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input |
|---------------|---|--|---------------------------------------|
| Aspinall 2013 | Pharmacist-managed ESA clinics: Pharmacists' scope of practice allowed them to dose and monitor ESA therapy. Patients at most sites were referred to the pharmacist-managed ESA clinic by a medical provider. Study clinics had been operational since at least August 1, 2008, and evidence-based protocols were in place for the management of patients receiving ESAs. Pharmacists were responsible for dosing and management of ESA therapy. Iron testing (ferritin, serum iron or TSAT) was performed. No further description was available. | Unknown  | NA                                    |
| Bucaloiu 2007 | A protocol-driven, pharmacist-managed program with monthly measurements of Hb and TSAT. Iron was given intravenously in the pharmacist group, not mentioned how this was in the physician-managed group.  | Unknown  | NA                                    |
| Debenito 2014 | A protocol-driven, pharmacist-managed program. ESA service operated under a Collaborative Drug Therapy Management agreement, whereby a clinical pharmacist and physician established written protocols authorising the pharmacist to manage drug therapy for a given indication, including initiation or discontinuation of specified medications, dose adjustment, and ordering appropriate laboratory tests. Patients were monitored using a population management database.  | Unknown  | NA                                    |

| Algorithm output | Algorithm available? | Level of detail of intervention description?<br>Description complete? | Quality of the intervention description | Is intervention reproducible? |
|------------------|----------------------|---|---|-------------------------------|
| NA               | NA                   | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| NA               | NA                   | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| NA               | NA                   | Intervention minimally described<br><br>Description not complete      | Low to moderate                         | No                            |

**Table 2.** Intervention description and algorithm characteristics (continued)

| Study           | Intervention description   | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input   |
|-----------------|--|--|---|
| Dubovetsky 2022 | Epoetin protocolized dosing was based on patient weight, Hb concentration, and subsequent Hb changes defined as percentage over a period of time. Patient's Hb values were measured every 2 to 4 weeks. Iron stores were assessed on a monthly basis by measuring ferritin and transferrin saturation (TSAT), according to preexisting practice standards. Epoetin alfa doses were administered via the IV route with each scheduled haemodialysis three times a week in accordance with preexisting practice by nephrologists on the unit. Epoetin adjustments varied based on the patient's Hb change over a 14-day period and current Hb concentration. Patients were screened by pharmacists for eligibility to receive parenteral iron sucrose; this was recommended for eligible patients if ferritin <1000 ng/mL and TSAT <25%. | Yes, manual  | Algorithm for epoetin alfa based on actual Hb and change in Hb  |
| El Nekidy 2020  | Dedicated, nephrology-trained pharmacists clinically dose and monitor ESA and iron therapies within a multidisciplinary team. Hb levels, iron indices, and ESA consumption were collected; Hb levels were measured monthly, and iron indices were measured quarterly according to guidelines. The nephrology-trained pharmacists monthly reviewed patient labs and devised the anaemia management plan. These plans were discussed during weekly rounds with the nephrologists.  | Yes, manual  | Algorithm for epoetin alfa based on actual Hb, change in Hb and symptoms. Differentiation between start or change of epoetin alfa. Algorithm for iron based on Hb, TSAT, and ferritin |
| Joy 2007        | Development of a multidisciplinary nephrology outpatient clinic for the management of renal anaemia. The clinical pharmacist co-ordered anaemia therapies and other drugs and conducted basic clinical assessments during patient visits. The patients were evaluated for response to therapies and assessed for complications of CKD. The clinical pharmacist also ordered laboratory tests pertinent to patient care; reviewed the test results; provided patient education concerning CKD, drugs, and diet; and coordinated indigent drug program entry for patients receiving erythropoietic agents.   | Yes, manual (ESA)  | Algorithm based on Hb values and changes in Hb  |

| Algorithm output   | Algorithm available? | Level of detail of intervention description?<br>Description complete?            | Quality of the intervention description | Is intervention reproducible? |
|--|----------------------|--|---|-------------------------------|
| Dose advice epoetin alfa:<br>Hold dose, -25%, no change, +25%  | Yes                  | Quite detailed intervention description<br><br>Intervention description complete | Moderate to high                        | Yes                           |
| Dose change: withhold epoetin alfa, decrease dose by 25 or 50% or increase dose up to 100%.<br>Start epoetin: 50-100 IU epoetin per kg/week<br>Iron: weekly, every two weeks, monthly, no iron (hold iron) | Yes                  | Intervention minimally described<br><br>Description not complete                 | Low                                     | No                            |
| Dose advice for ESA including dose and dosing interval   | Yes                  | Intervention reasonably described<br><br>Description not complete                | Moderate                                | No                            |

**Table 2.** Intervention description and algorithm characteristics (continued)

| Study        | Intervention description   | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input                           |
|--------------|--|--|---|
| Kimura 2004  | Pharmacists performed clinical activities , including four main activities as follows: 1) compiling guidelines for proper use of recombinant human erythropoietin in collaboration with physicians; 2) providing drug information on renal anaemia to physicians; 3) MUE (medication-use evaluation) based on laboratory test data; 4) Proposing plans to change prescriptions based on MUE  | Yes, manual  | Algorithm based on ferritin, Ht values, and changes in Ht;      |
| Linn 2023    | Pharmacist-led epoetin alfa-epbx (epoetin-zeta) initial dose consultation for hospitalised patients. Nephrologists consulted pharmacists through a haemodialysis order set or order browse. The consultation was an opt-out feature and was the default on the order set. The starting dose for epoetin-epbx was 50 units/kg iv 3 times a week. If a patient was already on ESA, the dose was converted (using the conversion table given).                                      | No   | NA  |
| Ohnishi 2011 | Pharmacists performed clinical management including five main activities 1) providing drug information on renal anaemia to physicians; 2) compiling guidelines for proper use of recombinant human erythropoietin and iron in collaboration with physicians; 3) medication use evaluation (MUE) based on laboratory data; 4) proposing plans to change prescriptions based on medication use evaluations and 5) providing drug information and lifestyle care point to patients. | Yes, manual  | Algorithm based on ferritin, TSAT, Hb values, and changes in Hb |
| Quercia 2001 | A drug use evaluation (DUE) protocol was set up, in which a pharmacist evaluated epoetin alpha doses. Monthly, the pharmacist provided dose recommendations for epoetin alpha and iron (full protocol available)   | No   | NA  |
| Rogers 2011  | A nurse-driven anaemia management protocol was implemented, based on a regional anaemia management protocol. Nurses were trained to use this protocol and to dose ESA and iron using this protocol.  | Yes, manual  | Algorithms for ESA and iron based on Hb, change in Hb, and TSAT |

| Algorithm output   | Algorithm available? | Level of detail of intervention description?<br>Description complete? | Quality of the intervention description | Is intervention reproducible? |
|--|----------------------|---|---|-------------------------------|
| ESA dose (start) plus change in ESA dose; iv iron (40 mg/week) cease or continue   | Yes                  | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| NA   | NA                   | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| ESA dose (maintain, increase or decrease one dose level)<br><br>Standard iv iron (ferric oxide) 40 mg when iron parameters low (ferritin ≤60 ng/ml and TSAT ≤ 20%) | Yes (for ESA)        | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| NA   | NA                   | Intervention reasonably described<br><br>Description not complete     | Moderate                                | No                            |
| ESA and iron dose; notification of the physician in specific situations (e.g. very low Hb, great Hb increases etcetera)  | Yes                  | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |

**Table 2.** Intervention description and algorithm characteristics (continued)

| Study  | Intervention description  | Algorithm-based? If yes, manual algorithm or computer-based? | Algorithm description including input  |
|--|---|--|--|
| <b>Observational, retrospective, cross-sectional study</b> |   |  |  |
| Gonzalez Fernandez 2013                                    | When ESA is prescribed, the pharmacist analyses the patient's pharmacotherapeutic profile (ESA dose and frequency) and evolution in time of Hb. In case of Hb >12.5 g/dL and no change in dosage, the pharmacist sends an email to the treating nephrologist to inform him of the patient's risk. In case of Hb >12.5 g/dL and dosage change, no action is taken. In case of Hb >13.5 g/dL or <8.5 g/dL and no dosage change, the pharmacist contacts the nephrologist by telephone to discuss how to proceed.    | Yes (partially described)                                    | Algorithm based on Hb values. Action described for Hb >12.5 g/dL and Hb <8.5 g/dL. No description for Hb >8.5 g/dL and 12.5 g/dL |
| <b>Study with an unknown design</b>                        |   |  |  |
| Walton 2005  | A clinical pharmacist monitored laboratory, medication, and other patient information to initiate and adjust erythropoietin and iron therapy on a monthly basis in the outpatient haemodialysis unit. The pharmacist wrote orders for each of the chronic haemodialysis patients, which were reviewed by the unit's medical director. Protocols for erythropoietin and iron therapy were developed by a multidisciplinary group of physicians, pharmacists, and nurses using the K-DOQI guidelines as a reference | Yes, manual  | Algorithms for ESA and iron based on Ht or Hb (ESA) and ferritin and TSAT (iron)   |

Abbreviations: DA: darbepoetin alfa; DUE: drug use evaluation; ESA: erythropoietin stimulating agents; Hb: haemoglobin; HD: haemodialysis; Ht: haematocrit; MUE: medication use evaluation; TSAT: transferrin saturation

In seven studies, ESA dosing was pharmacist-managed, and in one study, ESA dosing was algorithm-managed. In nine studies, pharmacist-managed and algorithm-managed dosing of ESA were combined. In six of the seven pharmacist-managed studies, it was unknown if an algorithm was used. In one study, no algorithms were used: dosing was protocol-based and pharmacist-managed.

The description of the algorithms was complete in all ten studies that used an algorithm. In six of these ten studies, algorithms were also used for iron dosing

10,22–26

| Algorithm output   | Algorithm available? | Level of detail of intervention description?<br>Description complete? | Quality of the intervention description | Is intervention reproducible? |
|--|----------------------|---|---|-------------------------------|
| Pharmacist action for Hb >12.5 g/dL; Hb >13.5 g/dL and Hb <8.5 g/dL                                      | No                   | Intervention minimally described<br><br>Description not complete      | Low                                     | No                            |
| Change in ESA dose in %: increase by 10, 15, or 25% and decrease with 20%; hold ESA or no change in dose | Yes                  | Intervention reasonably described<br><br>Description not complete     | Moderate                                | No                            |

In general, the quality of the intervention description was low to moderate and interventions were not reproducible. Five studies might be reproducible to some extent <sup>21,23,25,27,28</sup>, some variation in the execution of the intervention might, however, occur.

### Risk of bias and study quality

Data regarding the risk of bias and study quality are depicted in Table 3.

**Table 3.** Risk of bias, quality assessment, and design of included studies.

| Study                   | Risk of bias  | Quality assessment | Design                                       |
|-------------------------|---------------|--------------------|--|
| Van den Oever 2020      | Some concerns | Weak               | RCT  |
| Rogers 2011             | Serious       | Moderate           | Observational, retrospective cohort          |
| Aspinall 2012           | Serious       | Weak               | Observational, retrospective cohort          |
| Aspinall 2013           | Serious       | Weak               | Observational, retrospective cohort          |
| Debenito 2014           | Serious       | Weak               | Observational, retrospective cohort          |
| El Nekidy 2020          | Serious       | Weak               | Observational, retrospective cohort          |
| Dubovetsky 2022         | Serious       | Weak               | Observational, retrospective cohort          |
| Linn 2023               | Serious       | Weak               | Observational, retrospective cohort          |
| Gonzalez Fernandez 2013 | Serious       | Weak               | Observational, retrospective cross-sectional |
| Kimura 2004             | Serious       | Weak               | Observational, retrospective cohort          |
| Ohnishi 2011            | Serious       | Weak               | Observational, retrospective cohort          |
| Armstrong 2000          | Critical      | Weak               | RCT  |
| Dashti-Kavidaki 2012    | Critical      | Weak               | Interventional, pre-post                     |
| Bucaloiu 2007           | Critical      | Weak               | Observational, retrospective cohort          |
| Joy 2007                | Critical      | Weak               | Observational, retrospective cohort          |
| Quercia 2001            | Critical      | Weak               | Observational, retrospective cohort          |
| Walton 2005             | Critical      | Weak               | Design could not be determined               |

All but three included studies <sup>22,23,29</sup> were retrospective analyses. The risk of bias in observational studies was serious to critical as assessed with the ROBINS assessment tool. The risk of bias in the randomised controlled trials (RCTs) differed: the study of Armstrong & Cherrick <sup>22</sup> was classified as having a high risk of bias; the study of VandenOever et al <sup>23</sup> as having some concerns. Overall study quality was weak to moderate. The clinical trial register [clinicaltrials.gov](http://clinicaltrials.gov) did not

provide any evidence for bias due to missing results, as no trials without reported results were found.

### Data synthesis

Clinical and methodological heterogeneity was high between studies, due to differences in participants, study design, interventions, comparisons, and outcome parameters (Table 4).

Overall, we concluded that the clinical and methodological heterogeneity was too high to perform a meaningful meta-analysis, as recommended in the Cochrane Handbook for Systematic Reviews of Interventions <sup>30</sup>. However, data could be synthesised for pharmacist-managed renal anaemia for the haemoglobin outcome and ESA dose using standardised metrics as described below.

**Table 4.** Description of clinical and methodological heterogeneity.

|               | Description in studies (n)   |
|---------------|--|
| Participants  | A description of patient characteristics was missing in 4 studies, and limited (e.g. age, gender, ethnic background) in another 4 studies. In 9 studies, a more elaborate description of patient characteristics was provided. Mean patient age varied from 46 (1) to 75 (1, Veteran Affairs Medical Centres). In 3 studies, the mean patient age was around 55 years; in 6 studies, the mean age was around 65. The percentage of male participants varied between 45 and 68%, except for 1 study with 97% male participants (in Veteran Affairs Medical Centres). When described, the participants differed substantially in ethnic background, varying from 7% to 86% of patients of colour. Studies were conducted in patients with chronic kidney disease (7), haemodialysis (11), and peritoneal dialysis (1). |
| Interventions | ESA dosing: pharmacist-managed (7), algorithm-managed (1), combined pharmacist-managed and algorithm-managed (9). In 6 out of 7 pharmacist-managed studies, it was unknown if an algorithm was used.<br><br>The intervention descriptions were generally of low to moderate quality and insufficient to comprehend and reproduce the intervention. Only two studies (VandenOever and Dubovetsky) provided an intervention description of moderate to high quality.   |
| Comparisons   | Usual care by the nephrologist (15), primary care physician (1), no comparison (1)<br><br>Usual care was not further described in all but one study (VandenOever).   |

**Table 4.** Description of clinical and methodological heterogeneity. (continued)

|          | Description in studies (n)   |
|----------|--|
| Outcomes | <p>In eight studies, the outcome parameters were not clearly defined. In two studies, outcome parameters were not defined as primary or secondary.</p> <p>When the outcome parameters were described, they varied substantially: Hb in target range (6), Ht (3), monitoring laboratory parameters (2), time to achieve target Hb/Ht (3), iron status (7), iron dose (4), ESA dose (8), transfusions (4), and more (see also Supplementary Table 1)</p> |
| Design   | RCT (2), pre-post (1), observational with a control group (13): historical controls (8), other sites or primary care physician (3), USA average (1), other (1). In 1 study, no control group was mentioned.  |

### Study outcomes

Outcomes varied substantially between studies. Outcome categories most frequently reported were haemoglobin or haematocrit levels, ESA dose, ESA expenditure, iron status, and iron dose.

### Standardised metrics regarding haemoglobin and ESA for pharmacist-managed renal anaemia


The selected standardised metric regarding the haemoglobin outcome was the percentage of haemoglobin within target range in the intervention versus the control group. This metric was reported in six studies <sup>11,23,28,29,31,32</sup>. The characteristics of these studies are displayed in Table 5.

**Table 5.** Summary table: difference in percentage in target range for haemoglobin in pharmacist-managed renal anaemia versus the control group

| Study and population            | Type of intervention     | Study design                 | Risk of bias  | n   | p-value | difference in % haemoglobin in target range | 95% CI lowest value | 95% CI highest value |
|---------------------------------|--------------------------|------------------------------|---------------|-----|---------|---|---------------------|----------------------|
| Van den Oever 2020 HD           | Pharmacist and algorithm | RCT                          | Some concerns | 200 | 0.001   | 15.4  | 6.26                | 24.54                |
| Dubovetsky 2022 HD              | Pharmacist and algorithm | observational, retrospective | Serious       | 129 | 0.177   | 1.4   | -0.63               | 3.43                 |
| Gonzalez-Fernandez 2013 HD      | Pharmacist and algorithm | observational, retrospective | Serious       | 146 | <0.001  | 32  | 14.07               | 49.93                |
| Dashti-Kavidaki 2012 HD         | Pharmacist               | observational, retrospective | Critical      | 86  | 0.664   | -3.5  | -18.67              | 11.67                |
| Gonzalez-Fernandez 2013 CKD-NDD | Pharmacist and algorithm | observational, retrospective | Serious       | 135 | 0.2     | 15  | -7.87               | 37.87                |
| Aspinall 2012 CKD-NDD           | Pharmacist               | observational, retrospective | Serious       | 481 | <0.001  | 14.2  | 6.25                | 22.15                |
| Bucaloiu 2007 CKD               | Pharmacist               | observational, retrospective | Critical      | 134 | <0.001  | 25.9  | 11.39               | 40.41                |
| Gonzalez-Fernandez 2013 PD      | Pharmacist and algorithm | observational, retrospective | Serious       | 90  | 0.2     | 9   | -4.72               | 22.72                |

CI: confidence interval; CKD: chronic kidney disease; CKD-NDD: chronic kidney disease, non-dialysis dependent; HD: haemodialysis; PD: peritoneal dialysis; RCT: randomised controlled trial

A forest plot of the results of these studies regarding the haemoglobin outcome is displayed in Figure 2. The percentage in target range for haemoglobin in the intervention group varied between 3.5% lower (95%CI -18.67% to + 11.67%)<sup>29</sup> to 32.0% higher<sup>31</sup>(95%CI 14.07 to 49.93%) in the pharmacist-managed group versus the control group (n=1401).



**Figure 2.** Forest plot regarding the percentage of haemoglobin within target range in the intervention versus the control group.


The standardised metric regarding ESA dose was the relative ESA dose in the intervention versus the control group, as a percentage. This metric was calculated based on the actual dose of epoetin (alfa, beta or zeta) and darbepoetin alfa (DA) in the intervention versus the control group. ESA dose was reported in eight studies<sup>11,13,23,26,28,31-33</sup>. The characteristics of these studies are displayed in Table 6.

**Table 6.** Summary table: percentage reduction in ESA dose in pharmacist-managed renal anaemia versus the control group

| Study and population; pharmacist- and algorithm-managed or only pharmacist-managed renal anaemia | Study design                 | Risk of bias  | Type of ESA | n   | p-value | % reduction in ESA dose | 95% CI lowest value | 95% CI highest value |
|--|------------------------------|---------------|-------------|-----|---------|-------------------------|---------------------|----------------------|
| Van den Oever 2020 HD; P&A   | RCT                          | Some concerns | DA          | 200 | 0.02    | 27.51%                  | 4.30%               | 50.71%               |
| Linn 2023 HD; P  | observational, retrospective | Serious       | epo         | 536 | <0.001  | 26.16%                  | 11.50%              | 40.81%               |
| Ei Nekidy 2020 HD; P&A   | observational, retrospective | Serious       | epo         | 163 | 0.0556  | 7.73%                   | -0.20%              | 15.65%               |
| Gonzalez-Fernandez 2013 HD; P&A  | observational, retrospective | Serious       | DA          | 146 | 0.012   | 29.02%                  | 6.37%               | 51.67%               |
| Dubovetsky 2022 HD; P&A  | observational, retrospective | Serious       | epo         | 129 | 0.177   | 33.91%                  | -15.22%             | 83.03%               |
| Aspinall 2012 CKD-NDD; P   | observational, retrospective | Serious       | DA          | 481 | 0.049   | 26.28%                  | 0.07%               | 52.49%               |
| Gonzalez-Fernandez 2013 CKD-NDD; P&A   | observational, retrospective | Serious       | DA          | 135 | 0.001   | 49.97%                  | 20.32%              | 79.61%               |
| Debenito 2014 CKD-NDD; P   | observational, retrospective | Serious       | epo         | 101 | <0.001  | 19.89%                  | 8.75%               | 25.58%               |
| Bucaloiu 2007 CKD; P   | observational, retrospective | Critical      | epo         | 134 | <0.001  | 44.18%                  | 19.43%              | 68.94%               |
| Gonzalez-Fernandez 2013 PD; P&A  | observational, retrospective | Serious       | DA          | 90  | 0.434   | 5.45%                   | -7.97%              | 18.87%               |

CI: confidence interval; CKD: chronic kidney disease; CKD-NDD: chronic kidney disease, non-dialysis dependent; DA: darbepoetin alfa; epo: epoetin alfa, beta or zeta; ESA: erythropoietin stimulating agent; HD: haemodialysis; P: pharmacist-managed renal anaemia; P&A: pharmacist- and algorithm-managed renal anaemia; PD: peritoneal dialysis; RCT: randomised controlled trial

The forest plot of the reduction in ESA dose in the intervention versus the control group is displayed in Figure 3. The range in reduction in ESA dose was 5.45% (95%CI -7.97% to + 18.87%)<sup>31</sup> to 49.97% (95%CI 20.32% to 79.61%)<sup>31</sup> in the pharmacist-managed group versus the control group.



**Figure 3.** Forest plot regarding the relative dose of ESA in the intervention versus the control group.

## Qualitative description of iron outcomes

### Iron status

Seven studies reported iron status (transferrin saturation or ferritin levels or both) as outcome<sup>23-26,28,29,32</sup>. In five of seven studies, iron status was significantly higher in the intervention group<sup>23,26,28,29,32</sup>. No significant difference in iron status was found in one study, which was a non-inferiority study<sup>24</sup>. One study did not report statistical significance<sup>25</sup>.

### Iron dose

Four studies reported on iron doses as outcome<sup>23,24,26,28</sup>. One of these studies reported a significantly higher iron dose in the intervention group<sup>23</sup>, whereas the other three studies reported no significant difference<sup>24,26,28</sup>. The iron dose in the study from Dubovetsky and colleagues showed a trend towards a higher total iron dose in the intervention group (1200 mg vs 900 mg,  $p=0.060$ )<sup>28</sup>.

## Discussion

In this systematic review, we show that evidence regarding algorithm-managed and pharmacist-managed dosing of erythropoietin-stimulating agents in renal anaemia is scarce and generally of low to moderate quality with a substantial risk of bias. Only two randomised, controlled trials could be identified; all other studies were observational in nature and follow-up was relatively short with a range of 6 to 13 months.

Meta-analysis was not possible due to heterogeneity and high risk of bias. However, standardised metrics regarding haemoglobin outcome and ESA dose in this study suggest that pharmacist-managed dosing of ESA may improve the percentage in target range for haemoglobin and may reduce ESA dose. As meta-analysis was not possible, no definite conclusion could be drawn on the effectiveness of these strategies. Therefore, no GRADE recommendations could be provided.

Three previous systematic reviews reported on the effectiveness of pharmacist-managed renal anaemia as part of a review of all sorts of pharmacist interventions in patients with chronic kidney disease<sup>14,15</sup>. Salgado and colleagues concluded in 2012 that controlled and uncontrolled studies (n=8) on pharmacist-managed renal anaemia failed to demonstrate a significant impact on anaemia parameters and the high heterogeneity between studies precluded a quantitative synthesis of the results. On the other hand, Al Raiisi and colleagues<sup>14</sup> concluded in 2019, based on four studies published after the review of Salgado, that pharmacist-managed anaemia did improve haemoglobin outcomes<sup>10,11,13,34</sup>. Recently, Ardavani et al also concluded in their systematic review that pharmacist-managed renal anaemia improved haemoglobin outcomes<sup>16</sup>. However, we have serious concerns regarding the internal and external validity of the haemoglobin outcome in this last systematic review. Our three concerns regarding the internal validity relate to the choice of haemoglobin outcome parameter, the methodology, and the risk of bias of included studies. First, regarding the haemoglobin outcome, Ardavani et al reported an increase in haemoglobin of 0.76 g/dL (0.47 mmol/L) in the intervention versus the control group. However, they did not take into account the differences in baseline haemoglobin levels between the intervention and the control groups. Second, the risk of bias was not reported per study, but only as part of a general

quality assessment. Third, in the three RCTs included in the meta-analysis regarding the haemoglobin outcome, haemoglobin was one of several primary or secondary outcome parameters; none of these RCTs were specifically designed to determine the effect of pharmacist-managed renal anaemia on haemoglobin. Regarding the external validity of the haemoglobin outcome in the systematic review of Ardavani et al, we have concerns about the origin of the three included RCTs, as they all were performed in non-Western countries (India, Iraq, and Jordan). We therefore doubt that these results are representative of clinical practice in Europe and other Western countries. To underscore this concern, the included RCT from Mateti et al from India reported very low haemoglobin levels, especially in the governmental hospital setting. All in all, we think that the conclusions of the previous three systematic reviews may not represent the true effects of pharmacist-managed renal anaemia, due to the high risk of bias and heterogeneity of available literature and limited internal and external validity of the three systematic reviews.

This systematic review has several strengths. First of all, the included studies were performed in different countries, which suggests that the interventions can be performed in multiple health system models. Second, the absence of restrictions regarding study outcomes helped us to cover all possible outcomes to provide a wide overview of all possible benefits of algorithm-managed and pharmacist-managed dosing of ESA in patients with chronic kidney disease. Third, we followed all recommendations regarding registering and performing systematic reviews: the protocol was registered with PROSPERO, the international prospective register of systematic reviews. Furthermore, the protocol was drafted following PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) standards. Last, this systematic review was conducted and reported following PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) guidelines.

Of course, this systematic review also has limitations. First, the quality of the included studies was generally low to moderate. Only two randomised controlled trials and one interventional prospective study could be included. All other studies had an observational design, were often uncontrolled, generally had a poor description of the studied intervention, and provided limited information about the included population. In several studies, P-values or other measures of statistical significance were not mentioned, which made it impossible to determine the precision of the effect estimate. All these limitations preclude a

definite conclusion on the effectiveness of algorithm-managed and pharmacist-managed dosing of ESA in patients with renal anaemia.

Second, the high risk of bias and the large degree of heterogeneity between studies did not permit combining the study results into a formal meta-analysis. However, standardised metrics for haemoglobin and ESA dose suggest that pharmacist-managed dosing of ESA may improve the percentage in target range for haemoglobin and reduce ESA dose.

Third, we did not contact the authors for further details on the interventions if the intervention description was unclear. This was a deliberate choice as we aimed to determine the reproducibility of the method as described in the original publication.

Finally, an inherent limitation of all reviews is the inclusion of published literature only. Although our search was performed in several databases, we consulted clinicaltrials.gov, and included some studies with negative results, we cannot exclude publication bias towards studies with positive findings.

## Conclusions

Available evidence on the effectiveness of algorithm-managed and pharmacist-managed dosing of ESA in renal anaemia was scarce and showed heterogeneous results, with a high risk of bias. Therefore, no definite conclusions could be drawn on the effectiveness of both strategies. Consequently, recommendations on the implementation of either of the two strategies could not be made. However, there is some evidence of low to moderate quality that pharmacist-managed dosing of erythropoietin-stimulating agents in renal anaemia may improve the percentage in target range for haemoglobin and reduce ESA dose. This effect may be explained by better guideline adherence and improved prescribing of ESA and iron. Prospective and randomised studies of better quality are needed to provide evidence that can lead to broad implementation in clinical practice.

## Acknowledgments

We would like to thank the librarian of the LUMC for her assistance with the literature searches.

## References

1. Liabeuf S, Stralen KJ Van, Caskey F, et al. Attainment of guideline targets in EURODOPPS haemodialysis patients: are differences related to a country's healthcare expenditure and nephrologist workforce? *Nephrol Dial Transplant*. 2017;32(10):1737-1749. doi:10.1093/ndt/gfw409
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int Suppl* (2011). 2012;2(4):279-335. doi:10.1038/kisup.2012.40
3. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. *Clinical Journal of the American Society of Nephrology*. 2007;2(6):1274-1282. doi:10.2215/CJN.02380607
4. Singh AK, Szczech L, Tang KL, et al. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease for the CHOIR Investigators\*. 2006;20(16). Accessed December 10, 2017. <http://www.nejm.org/doi/pdf/10.1056/NEJMoa065485>
5. Jones M, Ibels L, Schenkel B, Zagari M. *PERSPECTIVES IN RENAL MEDICINE Impact of Epoetin Alfa on Clinical End Points in Patients with Chronic Renal Failure: A Meta-Analysis*. Vol 65.; 2004.
6. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: A position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). *Nephrology Dialysis Transplantation*. 2009;24(2):348-354. doi:10.1093/ndt/gfn653
7. Yilmaz I, Ozkok A, Kostek O, et al. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients. *Ren Fail*. 2016;38(1):89-95. doi:10.3109/0886022X.2015.1106896
8. Gaweda AE, Aronoff GR, Jacobs AA, Rai SN, Brier ME. Individualized Anemia Management Reduces Hemoglobin Variability in Hemodialysis Patients. *Journal of the American Society of Nephrology*. 2014;25(1):159-166. doi:10.1681/ASN.2013010089
9. Hara K, Mizutani Y, Kodera H, Miyake M, Yasuda Y, Ohara S. Successful creation of an anemia management algorithm for hemodialysis patients. *Int J Nephrol Renovasc Dis*. 2015;8:65-75. doi:10.2147/IJNRD.S80723
10. Ohnishi J, Miyake A, Kuwatsuka K, et al. Effect of Pharmacist Management on Serum Hemoglobin Levels with Renal Anemia in Hemodialysis Outpatients. *Biol Pharm Bull*. 2011;34(10):1609-1612. doi:10.1248/bpb.34.1609
11. Aspinall SL, Cunningham FE, Zhao X, et al. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD. *American Journal of Kidney Diseases*. 2012;60(3):371-379. doi:10.1053/j.ajkd.2012.04.013

12. Aspinall SL, Smith KJ, Good CB, et al. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients. *Appl Health Econ Health Policy*. 2013;11(6):653-660. doi:10.1007/s40258-013-0057-6
13. Debenito JM, Billups S, Tran T, Price L. Impact of a Clinical Pharmacy Anemia Management. *Journal of Managed Care & Specialty Pharmacy JMCP July*. 2014;20(7):715-720. Accessed February 25, 2018. www.amcp.org
14. Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, Cunningham S. Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review. *Int J Clin Pharm*. 2019;41(3):630-666. doi:10.1007/s11096-019-00816-4
15. Salgado TM, Moles R, Benrimoj SJ, Fernandez-Llimos F. Pharmacists' interventions in the management of patients with chronic kidney disease: A systematic review. *Nephrology Dialysis Transplantation*. 2012;27(1):276-292. doi:10.1093/ndt/gfr287
16. Ardavani A, Curtis F, Hopwood E, et al. Effect of pharmacist interventions in chronic kidney disease: a meta-analysis. *Nephrol Dialysis Transpl*. Published online 2024. doi:10.1093/ndt/gfae221/7816383
17. Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. *The BMJ*. 2019;366. doi:10.1136/bmj.l4898
18. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ (Online)*. 2016;355. doi:10.1136/bmj.i4919
19. McKenzie J, Brennan S. Synthesizing and presenting findings using other methods . In: Higgins J, Thomas J, Chandler J, et al., eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 6.5. Cochrane; 2024. Accessed September 16, 2024. www.training.cochrane.org/handbook
20. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. *The BMJ*. 2020;368. doi:10.1136/bmj.l6890
21. Quercia RA, Abrahams R, Pharm BS, White CM, D'avella J, Campbell M. Cost Avoidance and Clinical Benefits Derived from a Pharmacy-Managed Anemia Program. *Hosp Pharm*. 2000;36(2):169-175.
22. Armstrong EP, Cherrick RE. Epoetin Alfa Drug Use Evaluation Using A Software System:Lessons Learned. *Dis Manage Health Outcomes* . 2000;8(5):287-295.
23. van den Oever FJ, Heetman-Meijer CFM, Birnie E, Vasbinder EC, Swart EL, Schrama YC. A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial. *Pharmacol Res Perspect*. 2020;8(4):1-8. doi:10.1002/prp2.628
24. Rogers J, Leung M, Beaulieu M, Levin A, Burnett S, Zienkiewicz A. Evaluation of anemia management by algorithms in patients with chronic kidney disease who are not receiving dialysis. *Can J Hosp Pharm*. 2011;64(2):141-146. Accessed January 28, 2018. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093421/pdf/cjhp-64-2-141.pdf>

25. Walton T, Holloway KP, Knauss MD. Pharmacist-Managed Anemia Program in an Outpatient Hemodialysis Population. *Hosp Pharm*. 2005;40:1051-1056.
26. El Nekidy WS, Kadri A, Lee-St John TJ, Ghazi IM, Soong, Derrick C. Role of nephrology pharmacists in the management of anemia in outpatient dialysis units: a Canadian model. *Clin Nephrol*. 2020;94(1):36-42.
27. Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. *Pharmacotherapy*. 2007;27(5):734-744. doi:10.1592/phco.27.5.734
28. Dubovetsky D, Tyler J, Bisceglia S. Assessing impact of an interdisciplinary erythropoiesis-stimulating agent dosing protocol at an outpatient community hospital hemodialysis unit. *JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY*. Published online July 15, 2022. doi:10.1002/jac5.1675
29. Dashti-Khavidaki S, Khalili H, Shahverdi S, Abbasi MR, Lessan-Pezeshki M. The role of clinical pharmacy services in achieving treatment targets in Iranian haemodialysis patients. *Singapore Med J*. 2012;53(9):599-603. Accessed January 28, 2018. <https://www.sma.org.sg/UploadedImg/files/SMJ/5309/5309a7.pdf>
30. Deeks J, Higgins J, Altman D, McKenzie J, Angeliki Veroniki A. The Cochrane Handbook on Systematic Reviews of Interventions; Chapter 10: Analysing data and undertaking meta-analyses. <https://training.cochrane.org/handbook/current/chapter-10#section-10-2>. 2024. Accessed January 13, 2025. <https://training.cochrane.org/handbook/current/chapter-10>
31. Gonzalez Fernandez M, Roldan Sevilla T, Herrero Ambrosio A. Optimization use of stimulating factors of erythropoiesis. *European Journal of Clinical Pharmacy*. 2013;15:321-328.
32. Bucaloiu ID, Akers G, Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. *Manag Care Interface*. 2007;20(6):26-30. Accessed February 25, 2018. <http://www.ncbi.nlm.nih.gov/pubmed/17708080>
33. Linn E, Morrison H, Sanchez M, Heierman T. Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients. *Am J Health Syst Pharm*. 2023;80(11):687-691. doi:10.1093/ajhp/zxad004
34. Venkat Mateti U, Naik Nagappa A, Prabhu Attur R, Prasad Nagarapu S, Rangaswamy D. *Impact of Pharmaceutical Care on the Health-Related Quality of Life among Hemodialysis Patients-A Multicenter Randomized Controlled Study*. Vol 28.; 2017. Accessed May 28, 2019. <http://www.sjkdt.org>

